Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLTP | P55058 | 14/20 | 0.66 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RRM1 | P23921 | 1/20 | 0.45 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304017 | 0.91 | PLTP (0.63) | PLTPTOP1NPC1KMT2ASMN1; SMN2 | |
| SCHEMBL1304878 | 0.80 | PLTP (1.00) | PLTPTOP1KMT2AALDH1A1RAB9A | |
| SCHEMBL1302933 | 0.79 | ADORA1 (0.55) | PLTPNPC1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1302909 | 0.78 | PLTP (1.00) | PLTPTOP1 | |
| SCHEMBL1305129 | 0.77 | PLTP (1.00) | PLTPTOP1 | |
| SCHEMBL1304132 | 0.75 | CETP (0.53) | KMT2ASMN1; SMN2ALDH1A1RAB9AKDM4E | |
| SCHEMBL1305132 | 0.75 | PLTP (0.73) | PLTPTOP1ALDH1A1RRM1RRM2B | |
| Coh-29 SCHEMBL29424344 | 0.74 | PLTP (0.61) | PLTPTOP1NPC1KMT2ASMN1; SMN2 | |
| Coh-29 SCHEMBL10036527 | 0.74 | PLTP (0.61) | PLTPTOP1NPC1KMT2ASMN1; SMN2 | |
| Coh-29 SCHEMBL31436912 | 0.74 | PLTP (0.61) | PLTPTOP1NPC1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772488-B1 | 2,4,5-trisubstituted thiazole compounds,preparation methods,pharmaceutical compositions and medical uses thereof | INST PHARM & TOXICOLOGY AMMS (CN) | 2016-11-02 | — | — | EP | claimed |
| EP-2042494-B1 | 2,4,5-TRISUBSTITUTED THIAZOLE COMPOUNDS,PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2014-07-09 | — | — | EP | claimed |
| US-8053581-B2 | Trisubstituted thiazole compounds, preparations methods, pharmaceutical compositions and medicals uses thereof | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.C. China (CN) | 2011-11-08 | — | — | US | claimed |
| US-20090298832-A1 | TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2009-12-03 | — | — | US | claimed |
| EP-2042494-A1 | 2,4,5-TRISUBSTITUTED THIAZOLE COMPOUNDS,PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 2009-04-01 | — | — | EP | claimed |
| EP-2772488-B1 | 2,4,5-trisubstituted thiazole compounds,preparation methods,pharmaceutical compositions and medical uses thereof | INST PHARM & TOXICOLOGY AMMS (CN) | 2016-11-02 | — | — | EP | disclosed |
| EP-2772488-A1 | 2,4,5-trisubstituted thiazole compounds,preparation methods,pharmaceutical compositions and medical uses thereof | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L. A. China (CN) | 2014-09-03 | — | — | EP | disclosed |
| EP-2042494-B1 | 2,4,5-TRISUBSTITUTED THIAZOLE COMPOUNDS,PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2014-07-09 | — | — | EP | disclosed |
| US-8053581-B2 | Trisubstituted thiazole compounds, preparations methods, pharmaceutical compositions and medicals uses thereof | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.C. China (CN) | 2011-11-08 | — | — | US | disclosed |
| US-20090298832-A1 | TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2009-12-03 | — | — | US | disclosed |
| EP-2042494-A1 | 2,4,5-TRISUBSTITUTED THIAZOLE COMPOUNDS,PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298832-A1 | TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF | CETP, PLTP, MTTP | PLTP 2/4885TOP1 1474/4885NPC1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.